



Q & M DENTAL GROUP (SINGAPORE) LIMITED
(Company Registration Number 200800507R)
(Incorporated in the Republic of Singapore)

CLARIFICATION ON THE BUSINESS TIMES' ARTICLE PUBLISHED ON 10 JUNE 2024

The board of directors (the “**Board**”) of Q & M Dental Group (Singapore) Limited (the “**Company**”, and together with its subsidiaries, the “**Group**”) refers to The Business Times’ article published on 10 June 2024 titled “*Q & M is ready to reap its investments in AI, tech*” (the “**Article**”).

The Company wishes to make clarifications to the following statements made in the Article:

- (A) *“We do 14,000 scaling procedures every month. If we are able to get the patient to see the doctor, and the doctor can advise the patient to come back, we can multiply the scaling procedures by two to three times,” said Dr Ng, who estimates that this can grow the group’s revenue by 10 per cent.*”

“Dr Ng estimates that these two services can expand the group’s bottom line by at least 10 to 20 per cent. But, anticipating that there will be teething issues, he is “not putting a lot of hope to see immediate numbers.””

Company’s clarification

It has come to the attention of the Board that the above statements presented in the Article could have been interpreted as definitive projections of future profits. The Board recognises the importance of providing shareholders with accurate and transparent information. While the Group maintains an optimistic outlook regarding the potential of the Group’s artificial intelligence (“**AI**”) project, which aims to aid dentists in creating custom treatment plans incorporating preventative care and encouraging patients to return for scaling and cleaning appointments more frequently, the Board wishes to clarify that the figures mentioned are expectations rather than quantifications of future profits. As stated in the Article, it is anticipated that there will be “*teething issues*” during the implementation of these new initiatives, which may affect the timeline and potential for revenue growth.

In addition, the Board wishes to reaffirm that the Group’s priority remains on delivering superior treatment to its patients. The Group’s investment in the AI platform is ultimately driven by its unwavering commitment to improve patients’ overall well-being and long-term oral health. The AI platform was conceived to aid dentists in creating customised treatment plans, incorporating preventative care and encouraging regular check-ups, including scaling and cleaning, to safeguard patients against future complications. The Group’s emphasis on AI and preventative measures is rooted in the Group’s belief that greater transparency in helping patients make informed decisions regarding their treatment plans and oral health as the starting point is not only ethically sound, but financially prudent.

- (B) *“Q&M achieved robust earnings during the Covid-19 pandemic, on the back of its medical laboratory segment, following the acquisition of a 49 per cent stake in Acumen Diagnostics in 2021.”*

Company’s clarification

The Board wishes to highlight that in 2021, it was Aoxin Q & M Dental Group Limited, an associated company of the Group, and not the Company, that had acquired a 49% stake in Acumen Diagnostics. Furthermore, the Board wishes to clarify that the Company has a 51% direct shareholding in Acumen Diagnostics and a total effective shareholding of 67.07% in Acumen Diagnostics.

Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company. Persons who are in doubt as to the action they should take should consult their stockbrokers, bank managers, solicitors, accountants or other professional advisers.

By Order of the Board

Ng Sook Hwa
Chief Financial Officer
12 June 2024